-
Mashup Score: 0Columvi Plus GemOx May Improve Survival in R/R DLBCL - 4 day(s) ago
The phase 3 STARGLO study met its primary endpoint of improved overall survival, according to Columvi’s manufacturer, Genetech.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3
Join us for a free webinar covering the latest information for patients and caregivers. To register by phone, call (855) 709-3274. Topics Covered We invite you to learn more about: Treatment advances for Hogkin lymphoma Side-effect management Treatment options for relapse/refractory patients Monitoring for long term and late effects The importance of discussing quality-of-life issues with your healthcare team Speaker Jeremy Abramson, MD Director, Jon and Jo Ann Hagler Center for Lymphoma Massachusetts General Hospital Cancer Center Associate Professor of Medicine Harvard Medical School Boston, MA Submit a question for Dr. Abramson to answer during the Q&A session. Program Support Support for this program provided by The Leukemia & Lymphoma Society . < Back to Webcasts
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2New CAR-T Therapy Safe and Efficacious for Non-Hodgkin Lymphoma - 11 day(s) ago
The novel CAR-T cell therapy, HR001, showed promise in a recent trial of patients with relapsed or refractory non-Hodgkin lymphoma.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3Finding Cancer Cures at Any and All Costs - 15 day(s) ago
It was disconcerting to me when my oncologist was unsure about the treatment he was giving me and knew what the next would be without giving the first a chance.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 14Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma - 21 day(s) ago
Hoang et al. shows that DNA methyltransferase 3A (DNMT3A) regulates cellular energy production in mitochondria and contributes to the resistance of mantle cell lymphoma to ibrutinib, an inhibitor of Bruton tyrosine kinase. Targeting DNMT3A with low-dose decitabine is a potential therapeutic strategy to overcome ibrutinib resistance.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1My Food Choice Journey After Cancer - 1 month(s) ago
For 14 years, I’ve been dealing with small lymphocytic lymphoma, and want to maintain a healthier diet.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 6A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma - 2 month(s) ago
Background:In situ vaccination for the treatment of cancer aims to trigger an immune response locally that propagates systemically. We have shown that local tre
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Source: www.fda.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
The Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma clinical and laboratory/translational research.
Source: lymphoma.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma - 2 month(s) ago
Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cance
Source: www.businesswire.comCategories: General Medicine News, Onc News and JournalsTweet
Columvi plus chemotherapy improved overall survival compared to Rituxan plus chemo in patients with #lymphoma, according to findings from the phase 3 STARGLO trial. https://t.co/Pf4OS313zp